HCMC – Vietnam will cooperate with France’s Xenothera to conduct the third phase of the clinical trial for its XAV-19 Covid-19 treatment drug and access the transfer of its production technology, the Ministry of Health announced today, September 8.
Deputy Minister of Health Tran Van Thuan on September 6 held an online working session with Xenothera to discuss the cooperation.
XAV-19, a polyclonal antibody, was developed by the French firm based on its patented antibody production technology, according to the ministry.
The clinical trials in the first and second phases showed positive results in terms of the safety and efficacy of XAV-19 in preventing the health condition of Covid-19 patients from worsening, neutralizing the virus and reducing inflammation.
The results also showed that XAV-19 works well against the initial strain of the coronavirus and relevant variants, the local media reported.
The third phase of the XAV-19 clinical trials is being conducted in France and some European countries such as Greece, Bulgaria, Romania and Spain.
Xenothera President Odile Duvaux said that the company was willing to cooperate with Vietnam to conduct the third phase of the trials and to engage in further discussions on the transfer of the drug production technology to Vietnam.
Earlier in late May, the Ministry of Health and the Solidarity of France ordered 30,000 doses of XAV-19 from Xenothera.
Deputy Minister Thuan said that Vietnam’s readiness to cooperate with Xenothera in carrying out the third phase of clinical trials of XAV-19 and receiving the technology was aimed at diversifying sources of Covid treatment drugs to quickly bring the pandemic under control.
